ADC Therapeutics SA EBITDA Margin 2019-2023 | ADCT

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for ADC Therapeutics SA (ADCT) over the last 10 years. The current EBITDA margin for ADC Therapeutics SA as of March 31, 2023 is .
ADC Therapeutics SA EBITDA Margin Historical Data
2023-03-31 $0.18B $-0.13B -73.08%
2022-12-31 $0.21B $-0.12B -58.37%
2022-09-30 $0.16B $-0.17B -111.54%
2022-06-30 $0.09B $-0.23B -245.16%
2022-03-31 $0.08B $-0.23B -286.25%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.175B $0.210B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.076B 8.19
GSK (GSK) United Kingdom $70.106B 9.78
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.491B 22.15
Ginkgo Bioworks Holdings (DNA) United States $3.170B 0.00
Arcus Biosciences (RCUS) United States $1.611B 0.00
Biohaven (BHVN) United States $1.059B 0.00
Emergent Biosolutions (EBS) United States $0.412B 0.00
Enzo Biochem (ENZ) United States $0.114B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00